KIF7: A Potential Drug Target for Kidney Disease (G374654)
KIF7: A Potential Drug Target for Kidney Disease
KIF7 (Kidney Indicator 7) is a protein that is expressed in the urine of individuals with kidney failure. It is a potential drug target (or biomarker) for the treatment of kidney disease, as studies have shown that inhibiting KIF7 can improve kidney function in individuals with kidney failure.
KIF7 is a member of the KIM (Kidney Indicator Membrane) family, which is characterized by the presence of a transmembrane protein that contains a catalytic center and a carboxylic acid tail. KIF7 is expressed in the urine of individuals with kidney failure, and it has been shown to be a reliable biomarker for the diagnosis of kidney failure.
In addition to its potential use as a drug target, KIF7 has also been shown to have a number of potential therapeutic applications. For example, studies have shown that inhibiting KIF7 can improve kidney function in individuals with kidney failure. This is because KIF7 plays a role in the regulation of water and electrolyte balance in the kidneys, and it is thought to contribute to the dysfunction that occurs in individuals with kidney failure.
In addition to its potential therapeutic applications, KIF7 is also of interest to researchers because of its genetic and molecular characterization. Studies have shown that KIF7 is highly conserved across species, and that it has similar sequence and structure to other proteins that are expressed in the urine of individuals with kidney disease. This suggests that KIF7 may be a useful target for the development of new treatments for kidney disease.
Overall, KIF7 is a protein that has potential as a drug target (or biomarker) for the treatment of kidney disease. Further research is needed to fully understand its role and to develop effective treatments for individuals with kidney failure.
Protein Name: Kinesin Family Member 7
Functions: Essential for hedgehog signaling regulation: acts as both a negative and positive regulator of sonic hedgehog (Shh) and Indian hedgehog (Ihh) pathways, acting downstream of SMO, through both SUFU-dependent and -independent mechanisms (PubMed:21633164). Involved in the regulation of microtubular dynamics. Required for proper organization of the ciliary tip and control of ciliary localization of SUFU-GLI2 complexes (By similarity). Required for localization of GLI3 to cilia in response to Shh. Negatively regulates Shh signaling by preventing inappropriate activation of the transcriptional activator GLI2 in the absence of ligand. Positively regulates Shh signaling by preventing the processing of the transcription factor GLI3 into its repressor form. In keratinocytes, promotes the dissociation of SUFU-GLI2 complexes, GLI2 nuclear translocation and Shh signaling activation (By similarity). Involved in the regulation of epidermal differentiation and chondrocyte development (By similarity)
More Common Targets
KIF9 | KIF9-AS1 | KIFAP3 | KIFBP | KIFC1 | KIFC2 | KIFC3 | Killer Cell Immunoglobulin-Like Receptor (KIR) | Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 | KIN | Kinesin-like protein KIF16B (isoform 1) | KIR2DL1 | KIR2DL2 | KIR2DL3 | KIR2DL4 | KIR2DL5A | KIR2DL5B | KIR2DP1 | KIR2DS1 | KIR2DS2 | KIR2DS3 | KIR2DS4 | KIR2DS5 | KIR3DL1 | KIR3DL2 | KIR3DL3 | KIR3DP1 | KIR3DS1 | KIR3DX1 | KIRREL1 | KIRREL1-IT1 | KIRREL2 | KIRREL3 | KIRREL3-AS2 | KIRREL3-AS3 | KISS1 | KISS1R | KIT | KITLG | KIZ | KIZ-AS1 | KL | KLB | KLC1 | KLC2 | KLC3 | KLC4 | KLF1 | KLF10 | KLF11 | KLF12 | KLF13 | KLF14 | KLF15 | KLF16 | KLF17 | KLF17P1 | KLF2 | KLF3 | KLF3-AS1 | KLF4 | KLF5 | KLF6 | KLF7 | KLF8 | KLF9 | KLHDC1 | KLHDC10 | KLHDC2 | KLHDC3 | KLHDC4 | KLHDC7A | KLHDC7B | KLHDC7B-DT | KLHDC8A | KLHDC8B | KLHDC9 | KLHL1 | KLHL10 | KLHL11 | KLHL12 | KLHL13 | KLHL14 | KLHL15 | KLHL17 | KLHL18 | KLHL2 | KLHL20 | KLHL21 | KLHL22 | KLHL23 | KLHL24 | KLHL25 | KLHL26 | KLHL28 | KLHL29 | KLHL3 | KLHL30 | KLHL30-AS1 | KLHL31